1. Home
  2. NTRB vs NSRX Comparison

NTRB vs NSRX Comparison

Compare NTRB & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutriband Inc.

NTRB

Nutriband Inc.

N/A

Current Price

$3.14

Market Cap

36.0M

Sector

Health Care

ML Signal

N/A

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$3.40

Market Cap

38.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NTRB
NSRX
Founded
2016
2019
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
38.9M
IPO Year
2019
2024

Fundamental Metrics

Financial Performance
Metric
NTRB
NSRX
Price
$3.14
$3.40
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
8.1K
11.1K
Earning Date
05-29-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,036,651.00
N/A
Revenue This Year
$30.17
N/A
Revenue Next Year
$3,394.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$1.98
52 Week High
$8.63
$9.99

Technical Indicators

Market Signals
Indicator
NTRB
NSRX
Relative Strength Index (RSI) 57.64 48.64
Support Level $2.91 $2.83
Resistance Level $3.16 $3.60
Average True Range (ATR) 0.11 0.26
MACD 0.04 0.01
Stochastic Oscillator 77.83 36.76

Price Performance

Historical Comparison
NTRB
NSRX

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: